Axogen
AXGNAxogen is a leading medical technology company dedicated to the science and commercialization of regenerative medicine for peripheral nerve repair.
Earnings
Next report
Date not yet announcedValuation & ratios
Segments
By geography
Competitors
By market cap
By revenue growth
Profile
Axogen is a leading medical technology company dedicated to the science and commercialization of regenerative medicine for peripheral nerve repair. The company provides a comprehensive portfolio of surgical solutions designed to restore motor and sensory function for patients suffering from traumatic injuries or undergoing surgical procedures. Their platform offers clinically proven alternatives to traditional nerve autografts and synthetic conduits, aiming to improve quality of life and reduce chronic pain.
Axogen is the leading company focused specifically on peripheral nerve regeneration, utilizing proprietary processing methods to offer the first off-the-shelf nerve allograft.
Questions, answered.
- What is Axogen's market cap?
- Axogen (AXGN) has a market capitalization of $2.2B and trades on NASDAQ.
- What is Axogen's revenue and profitability?
- Axogen generated $251.2M in trailing twelve-month revenue with a net loss of $33.5M, representing a net margin of -13.4%. Gross margin stands at 74.6%, with free cash flow of -$266.0K. These figures are based on the Q2 2026 filing.
- Who are Axogen's competitors?
- Axogen's key competitors include Integra LifeSciences, Stryker Corporation, Baxter International, and others. These companies compete in similar markets and product categories.
- Where is Axogen headquartered?
- Axogen is headquartered in United States of America and employs approximately 428 people. It has been publicly traded since 1986.
